Clinical trials
Diffuse Astrocytoma clinical trials
Below are recruiting diffuse astrocytoma clinical trials, each written for real people, not researchers. We’re tracking 16 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05956821RecruitingPhase 1/Phase 2
Study drug for young people with recurring brain glioma
This Phase 1/2 trial tests a study treatment for children and young adults under 22 whose brain glioma has come back or isn’t responding to prior treatment. It’s designed to see whether the treatment is safe and effective for shrinking tumors in this situation.
Miami, FloridaAges 1–21 - NCT06161974RecruitingPhase 2
Olutasidenib and temozolomide for IDH1-mutant high-grade glioma
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Aurora, ColoradoAges 12–39 - NCT07468136RecruitingPhase 1/Phase 2
Retifanlimab with or without DFMO for progressive high-grade gliomas
This study tests a combination of two drugs—retifanlimab (an immunotherapy that helps your immune system fight cancer) and DFMO (a medicine that may stop tumor growth)—in people with high-grade brain tumors that are growing. Participants will receive these treatments before and after their planned surgery.
Rochester, MinnesotaAges 18 years+ - NCT04065776Recruiting
Proton therapy that avoids the hippocampus for slow brain tumors
This study tests a proton radiation plan designed to spare the hippocampus (a memory area) in children and teens with certain low-grade brain tumors. It may help deliver treatment to the tumor while reducing unwanted brain effects.
Rochester, MinnesotaAges 6–21 - NCT04541082RecruitingPhase 1
Oral ONC206 for recurrent brain and spinal tumors
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Bethesda, MarylandAges 18 years+ - NCT04623931RecruitingPhase 2
Chemo and radiation for IDH-wildtype glioma
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
Houston, TexasAges 18 years+ - NCT05843253RecruitingPhase 2
Ribociclib plus everolimus or temozolomide for certain brain tumors
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Aurora, ColoradoAges 1–39 - NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Aurora, ColoradoAges 1–39 - NCT05190172Recruiting
Proton versus photon radiation for IDH-mutated brain tumors
This trial compares two types of radiation—proton therapy versus photon (standard) therapy—for adults with an IDH-mutated grade 2 or 3 brain tumor. The goal is to see which approach works better and/or causes fewer side effects while treating the tumor.
OsloAges 18–65 - NCT07223034RecruitingPhase 1
A study of targeted radiation for PSMA-positive gliomas
This early-phase trial tests a radioactive drug called 177Lu-PSMA-617 for people with certain types of brain tumors (gliomas) that have a specific marker (PSMA). The drug targets and delivers radiation to the tumor cells. It may be an option if standard treatments have been completed.
Basking Ridge, New JerseyAges 18 years+ - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Beverly Hills, CaliforniaAges 18 years+ - NCT06896110Enrolling by invitationPhase 1
Spinal chemo and immunotherapy for recurrent high-grade glioma
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
Iowa City, IowaAges 13 years+ - NCT06630260RecruitingPhase 1/Phase 2
Avutometinib and Defactinib for brain tumors
This trial tests two oral drugs, avutometinib and defactinib, in people with aggressive brain tumors like glioblastoma. The goal is to see if this combination can shrink tumors or stop them from growing.
CambridgeAges 16 years+ - NCT06860594RecruitingPhase 1
Triapine plus radiation for recurrent brain tumors
This trial tests whether adding an experimental drug called triapine to a second round of radiation therapy can help treat brain tumors that have come back after initial treatment. It may be a good option for people with recurrent glioblastoma or astrocytoma who meet safety criteria.
Duarte, CaliforniaAges 18 years+ - NCT06333899RecruitingEarly Phase 1
Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Aurora, ColoradoAges 1–21 - NCT07608003Recruiting
MRI AI model study for midline brain tumors
This study uses artificial intelligence to analyze MRI scans of midline brain tumors (gliomas) to help predict how the disease may progress and improve treatment planning. Researchers are collecting data from multiple hospitals to teach an AI system to better understand these tumors.
Changsha, HunanAges Any age
Hear when a new Diffuse Astrocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diffuse astrocytoma?
- Yes. Clin2 currently lists 16 recruiting diffuse astrocytoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diffuse astrocytoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diffuse astrocytoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.